

Supplementary Table 1. Univariate analysis of prognostic factors for OS

Characteristic	Total	Median OS (mo)	<i>p</i> value
Age (yr)			0.017
80–83	80 (63.5)	10.1	
≥ 84	46 (36.5)	7.9	
Sex			0.971
Male	63 (50.0)	9.6	
Female	63 (50.0)	8.8	
ECOG PS			< 0.001
≤ 2	75 (59.5)	18.9	
> 2	51 (40.5)	3.5	
CCI			0.373
≤ 4	34 (27.0)	7.9	
> 4	92 (73.0)	9.3	
ISS			0.005
I, II	37 (30.8)	24	
III	83 (69.2)	7.9	
R-ISS			0.641
I, II	50 (52.1)	14.2	
III	46 (47.9)	8.9	
CRAB criteria			
Hemoglobin < 10 g/dL			0.918
Presence	94 (74.6)	8.2	
Absence	32 (25.4)	11.4	
Bone disease			0.714
Presence	84 (77.8)	7.9	
Absence	24 (22.2)	12.2	
Calcium > 11 mg/dL			0.007
Presence	11 (8.7)	1.6	
Absence	115 (91.3)	11.4	
Creatinine > 2 mg/dL			0.692
Presence	32 (25.6)	2.6	
Absence	93 (74.4)	10.1	
Lab			
Platelet < 100 × 10 ⁹ /L			0.007
Presence	32 (25.6)	3.5	
Absence	93 (74.4)	14.9	
Albumin < 3.5 g/dL			0.990
Presence	85 (67.5)	7.9	
Absence	41 (32.5)	13.3	
LDH elevation			0.423
Presence	48 (39.0)	7.7	
Absence	75 (61.0)	14.2	

Supplementary Table 1. Continued

Characteristic	Total	Median OS (mo)	<i>p</i> value
High-risk cytogenetic abnormalities			0.985
Presence	21 (22.3)	11.2	
Absence	73 (77.7)	14.9	
Treatment			< 0.001
Chemotherapy	85 (67.5)	16.4	
Best supportive care	41 (32.5)	1.9	
Year of diagnosis			0.527
2010	11 (8.7)	12.2	
2011	5 (3.9)	1.6	
2012	8 (6.3)	4.5	
2013	8 (6.3)	11.3	
2014	13 (10.2)	9.6	
2015	17 (13.4)	18.9	
2016	17 (13.4)	4	
2017	13 (10.2)	14.2	
2018	8 (6.3)	5.5	
2019	27 (21.3)	3.8	

Values are presented as number (%).

OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group Performance Status; CCI, Charlson comorbidity index; ISS, International Staging System; R-ISS, Revised International Staging System; CRAB, hypercalcemia, renal failure, anemia, and bone disease; LDH, lactate dehydrogenase.